Simdax

Simdax®

Levosimendan, see there.
Mentioned in ?
References in periodicals archive ?
7m of royalties paid to Abbott due to the acquisition of Simdax.
Orion and US-based Abbott Laboratories (NYSE: ABT) have started negotiations on the transfer of the marketing rights for the heart failure drug Simdax to Orion.
Abbott Laboratories (Abbott Park, IL) and Orion Corporation (Espoo, Finland) have expanded their licensing agreement for the injectable formulation of levosimendan (marketed as Simdax in most countries), Orion's proprietary drug for the treatment of acutely decompensated heart failure.
Contract notice: Supply of medicine (Corotrop, Norepinephrine, Simdax, Dobutamine admeda etc.
Due to the good operating profit for the first quarter, lower R&D expenditure than estimated earlier, as well as the signing fee from Abbott Laboratories for the revised licensing agreement concerning the heart failure drug Simdax, the consolidated full-year operating profit for the Orion Group is estimated to clearly improve from the previous year," Orion said.
Finnish pharmaceutical company Orion Corporation said on Thursday (2 October) that it had decided to withdraw its marketing authorisation application concerning the heart failure drug Simdax from the review process of the German regulatory drug authority BfArM (Bundesinstitut fur Arzneimittel und Medizinprodukte).